Global law firm Dentons has advised the Berlin-based EU Malaria Fund on a financing agreement with DMG Deutsche Malaria GmbH. DMG intends to use the funding to advance the development of its anti-malaria combination therapy.

The EU Malaria Fund (EUMF) combines funds from the European Union, the European Investment Bank, Investitionsbank Berlin, the Bill & Melinda Gates Foundation and other national and private European stakeholders. It aims to bridge the gap between research and the market and to provide innovative solutions for the prevention and treatment of serious infectious diseases. The EUMF is managed by Investitionsbank Berlin (IBB Group).

DMG is based in Hamburg and was founded in 2003 with the aim of battling malaria. DMG is developing a new combination therapy against the malaria pathogen Plasmodium falciparum, which consists of the three known drugs: fosmidomycin, clindamycin and artesunate. As all three substances have a short half-life, the triple combination is expected to improve and shorten the duration of the necessary treatment.

Led by Dr. Axel Schlieter with support from senior associate Julia Heitmann in Düsseldorf, Dentons once again advised the EU Malaria Fund on the venture loan in this transaction. The Firm also advised Investitionsbank Berlin on the establishment of the fund back in July 2020, and assisted the fund last year in financing transactions for biotech companies Achilles Vaccines (Italy) and Sanaria (US).